Total Payments
$329,365
2024 Payments
$54,045
Companies
51
Transactions
581
Medicare Patients
749
Medicare Billing
$126,238
Payment Breakdown by Category
Other$267,145 (81.1%)
Consulting$30,089 (9.1%)
Travel$18,669 (5.7%)
Food & Beverage$13,258 (4.0%)
Research$190.25 (0.1%)
Education$13.43 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $267,145 | 108 | 81.1% |
| Consulting Fee | $30,089 | 36 | 9.1% |
| Travel and Lodging | $18,669 | 59 | 5.7% |
| Food and Beverage | $13,258 | 375 | 4.0% |
| Unspecified | $190.25 | 1 | 0.1% |
| Education | $13.43 | 2 | 0.0% |
Payments by Type
General
$329,175
580 transactions
Research
$190.25
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $66,134 | 53 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $62,434 | 66 | $0 (2022) |
| Amgen Inc. | $48,449 | 75 | $0 (2024) |
| Janssen Biotech, Inc. | $41,061 | 81 | $0 (2024) |
| GENZYME CORPORATION | $40,445 | 34 | $0 (2024) |
| GlaxoSmithKline, LLC. | $29,502 | 20 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $21,384 | 20 | $0 (2024) |
| Celgene Corporation | $11,297 | 37 | $0 (2023) |
| Genentech USA, Inc. | $2,093 | 37 | $0 (2024) |
| Seagen Inc. | $1,375 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,045 | 54 | GlaxoSmithKline, LLC. ($27,430) |
| 2023 | $26,528 | 31 | AbbVie Inc. ($12,691) |
| 2022 | $38,830 | 39 | ABBVIE INC. ($18,976) |
| 2021 | $29,717 | 37 | Janssen Biotech, Inc. ($7,686) |
| 2020 | $24,783 | 24 | AbbVie Inc. ($7,500) |
| 2019 | $84,876 | 82 | E.R. Squibb & Sons, L.L.C. ($43,608) |
| 2018 | $62,666 | 167 | Janssen Scientific Affairs, LLC ($19,249) |
| 2017 | $7,920 | 147 | Amgen Inc. ($3,500) |
All Payment Transactions
581 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $139.07 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $44.22 | General |
| 12/05/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $38.05 | General |
| 11/14/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: BioOncology | ||||||
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $133.54 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/07/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $28.67 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $81.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $118.02 | General |
| Category: Hematology/Oncology | ||||||
| 10/23/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $43.61 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $114.55 | General |
| 10/10/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: Oncology | ||||||
| 10/09/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $659.00 | General |
| Category: Oncology | ||||||
| 10/03/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $46.00 | General |
| Category: Oncology | ||||||
| 07/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,350.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $190.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 148 | 356 | $105,355 | $27,530 |
| 2022 | 6 | 167 | 361 | $74,227 | $28,100 |
| 2021 | 7 | 204 | 452 | $108,625 | $36,506 |
| 2020 | 8 | 230 | 491 | $106,526 | $34,103 |
Total Patients
749
Total Services
1,660
Medicare Billing
$126,238
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 114 | $32,262 | $10,311 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 139 | $40,449 | $9,762 | 24.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 18 | $10,116 | $2,373 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 55 | $10,318 | $2,344 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $9,210 | $1,837 | 19.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $3,000 | $901.80 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 136 | $21,143 | $9,720 | 46.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 114 | $31,510 | $9,263 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 68 | $6,805 | $3,204 | 47.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 17 | $7,820 | $2,649 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $4,375 | $1,945 | 44.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 12 | $2,574 | $1,320 | 51.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 186 | $31,992 | $14,423 | 45.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 136 | $44,472 | $10,845 | 24.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 22 | $12,286 | $3,477 | 28.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 68 | $7,597 | $3,324 | 43.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 17 | $4,165 | $1,983 | 47.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $4,081 | $1,617 | 39.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 12 | $4,032 | $837.30 | 20.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 73 | 198 | $32,472 | $11,821 | 36.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 100 | $31,100 | $8,378 | 26.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 20 | 32 | $7,456 | $2,861 | 38.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 47 | $10,152 | $2,726 | 26.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 51 | 67 | $7,102 | $2,396 | 33.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $6,001 | $2,297 | 38.3% |
About Dr. Franklin Chen, M.D
Dr. Franklin Chen, M.D is a Hematology & Oncology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2008. The National Provider Identifier (NPI) number assigned to this provider is 1992979736.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Franklin Chen, M.D has received a total of $329,365 in payments from pharmaceutical and medical device companies, with $54,045 received in 2024. These payments were reported across 581 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($267,145).
As a Medicare-enrolled provider, Chen has provided services to 749 Medicare beneficiaries, totaling 1,660 services with total Medicare billing of $126,238. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Winston Salem, NC
- Active Since 04/14/2008
- Last Updated 07/11/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992979736
Products in Payments
- DARZALEX (Biological) $58,389
- VENCLEXTA (Drug) $55,600
- EMPLICITI (Biological) $48,994
- SARCLISA (Biological) $39,956
- Kyprolis (Biological) $32,743
- OJJAARA (Drug) $29,245
- Venclexta (Drug) $10,516
- OPDIVO (Biological) $9,192
- Kyprolis (Drug) $6,701
- XGEVA (Biological) $4,603
- TECVAYLI (Biological) $3,458
- Revlimid (Drug) $2,707
- ADCETRIS (Biological) $1,609
- Aliqopa (Drug) $950.00
- IMBRUVICA (Drug) $503.87
- CALQUENCE (Drug) $476.06
- JAKAFI (Drug) $293.86
- BLENREP (Biological) $256.06
- Imbruvica (Drug) $182.53
- TAGRISSO (Drug) $150.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Winston Salem
Dr. Angela Alistar, Md, MD
Hematology & Oncology — Payments: $468,976
Hematology & Oncology $468,976
Caio Max Rocha Lima, Md, MD
Hematology & Oncology — Payments: $361,035
Hematology & Oncology $361,035
Ravi Paluri, Md, MD
Hematology & Oncology — Payments: $327,857
Hematology & Oncology $327,857
Dr. Timothy Pardee, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $120,125
Hematology & Oncology $120,125
Leon Bernal-Mizrachi, Md, MD
Hematology & Oncology — Payments: $46,070
Hematology & Oncology $46,070
John Mckay, D.o, D.O
Hematology & Oncology — Payments: $12,986
Hematology & Oncology $12,986